GlassScriptPhysician profile
Joseph M Shaughnessy
NPI 1336236900
$4,366.10
in general payments reported to CMS, 2019-2025
29 companies · $534 in 2025
The $534 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $310 · 2021: $834 · 2022: $619 · 2023: $717 · 2024: $1,051 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.78 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $412.24 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $410.29 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $260.41 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.08 | 2021-2025 | |
| Antares Pharma, INC. | $207.84 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.07 | 2019-2022 | |
| Lilly USA, LLC | $195.84 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $178.35 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.79 | 2019-2024 | Xifaxan |
| Boston Scientific Corporation | $141.58 | 2024 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $117.01 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $111.02 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $80.93 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $73.41 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $66.87 | 2019-2021 | |
| Glaxosmithkline, LLC. | $64.23 | 2022-2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $55.19 | 2020-2022 | |
| Allergan, INC. | $46.81 | 2019-2020 | |
| Tris Pharma INC | $45.02 | 2024-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $39.45 | 2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $33.13 | 2021 | |
| Horizon Therapeutics Plc | $26.91 | 2020 | |
| Noven Therapeutics, LLC | $24.99 | 2024 | Xelstrym |
| Corcept Therapeutics | $22.10 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $19.51 | 2022 | |
| Pacira Therapeutics, INC. | $15.89 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.79 | 2025 | Rexulti |
| Shire North American Group INC | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Shaughnessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.